Pegvisomant — Discount Pricing

Other medications in Diabetes & Endocrine

• Bromocriptine
• Desmopressin Oral
• Hydrocortisone Oral
• Lanreotide

About Pegvisomant

Pegvisomant (brand name Somavert) is a crucial medication for individuals managing acromegaly, a rare hormonal disorder. At TheDrugClub, we understand the significant financial burden specialty medications can impose. Our mission is to help members navigate these costs, offering pathways to potential savings on vital prescriptions like pegvisomant.

What is Pegvisomant and What Does It Treat?

Pegvisomant is a specialized medication primarily used to treat acromegaly, a rare condition characterized by the body producing too much growth hormone (GH). This excess GH leads to an overproduction of insulin-like growth factor 1 (IGF-1), causing bones, cartilage, and soft tissues to grow excessively. Symptoms often include enlarged hands and feet, facial changes, headaches, joint pain, and an increased risk of serious health complications like heart disease and diabetes. Pegvisomant is typically prescribed when other treatments, such as surgery or somatostatin analogs, have not been effective or are not tolerated by the patient.

How Does Pegvisomant Work?

Unlike some other acromegaly treatments that aim to reduce growth hormone production, pegvisomant works differently. It is a growth hormone receptor antagonist. This means it acts by blocking the growth hormone receptors on cells throughout the body. By doing so, it prevents the excess growth hormone from binding to these receptors and exerting its effects. While pegvisomant doesn't lower the levels of growth hormone in the blood, it effectively normalizes IGF-1 levels, which is the key indicator of disease activity and the primary driver of acromegaly symptoms. This action helps to alleviate symptoms and reduce the long-term health risks associated with the condition. It is administered via subcutaneous injection, typically once daily.

Typical Costs and How TheDrugClub Can Help

Pegvisomant is a specialty medication, and as such, its cost can be substantial, often running into thousands of dollars per month depending on the dosage, pharmacy, and your specific insurance plan. These high costs can be a significant barrier to consistent treatment for many patients.

As a member of TheDrugClub, you have avenues to explore potential savings on pegvisomant. For specialty drugs like this, members may be eligible for active-formulary benefits if their health plan includes pegvisomant within its preferred drug list. This can significantly reduce your out-of-pocket expenses. Alternatively, even if pegvisomant isn't on your plan's active formulary, TheDrugClub can help you access discounted pricing through our extensive network of pharmacies. We work diligently to negotiate prices, aiming to make essential medications more affordable for our members.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Pegvisomant is approved for (FDA label)

SOMAVERT is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-1 (IGF-1) levels. SOMAVERT is a growth hormone receptor antagonist indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-1 (IGF-1) levels. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: December 18, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Pegvisomant (FDA label)

For injection: 10 mg, 15 mg, 20 mg, 25 mg or 30 mg white lyophilized powder in a single-dose vial for reconstitution supplied with a prefilled syringe containing 1 mL of diluent (Sterile Water for Injection, USP). For injection: 10 mg, 15 mg, 20 mg, 25 mg or 30 mg lyophilized powder in a single-dose vial for reconstitution supplied with a prefilled syringe containing 1 mL of diluent (Sterile Water for Injection, USP). ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 3cbb485b-6df1-49ce-8747-592b395b1988. SPL document ID: 36dc9264-0f75-4059-ac68-65fa4bfcdcc2. Label effective date: December 18, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Pegvisomant (FDA label)

Clinically significant adverse reactions that appear in other section of the labeling include: • Hypoglycemia Associated with GH Lowering in Patients with Diabetes Mellitus [see Warnings and Precautions (5.1) ] • Liver Toxicity [see Warnings and Precautions (5.2) ] • Cross-Reactivity with GH Assays [see Warnings and Precautions (5.3) ] • Lipohypertrophy [see Warnings and Precautions (5.4) ] • Systemic Hypersensitivity [see Warnings and Precautions (5.5) ] Elevations of serum concentrations of ALT and AST greater than ten times the ULN were reported in two patients (0.8%) exposed to SOMAVERT in pre-approval clinical studies.

Source: FDA prescribing information (DailyMed). Set ID: 3cbb485b-6df1-49ce-8747-592b395b1988. SPL document ID: 36dc9264-0f75-4059-ac68-65fa4bfcdcc2. Label effective date: December 18, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Pegvisomant (FDA label)

None. None. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 3cbb485b-6df1-49ce-8747-592b395b1988. SPL document ID: 36dc9264-0f75-4059-ac68-65fa4bfcdcc2. Label effective date: December 18, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Pegvisomant (FDA label)

• Hypoglycemia : Monitor blood glucose in patients with diabetes mellitus and reduce anti-diabetic drug therapy as necessary. ( 5.1 ) • Liver Toxicity: Should have more frequent liver tests and/or discontinue SOMAVERT. ( 5.2 ) • Systemic Hypersensitivity : Monitor closely when re-initiating SOMAVERT in patients with systemic hypersensitivity. ( 5.5 ) 5.1 Hypoglycemia Associated With GH Lowering in Patients With Diabetes Mellitus GH opposes the effects of insulin on carbohydrate metabolism by decreasing insulin sensitivity; thus, glucose tolerance may improve in some patients treated with SOMAVERT. Patients should be carefully monitored and doses of anti-diabetic drugs reduced as necessary to avoid hypoglycemia in patients with diabetes mellitus. 5.2 Liver Toxicity Baseline serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum total bilirubin (TBIL), and alkaline phosphatase (ALP) levels should be obtained prior to initiating therapy with SOMAVERT. Table 1 lists recommendations regarding initiation of treatment with SOMAVERT, based on the results of these liver tests (LTs).

Source: FDA prescribing information (DailyMed). Set ID: 3cbb485b-6df1-49ce-8747-592b395b1988. SPL document ID: 36dc9264-0f75-4059-ac68-65fa4bfcdcc2. Label effective date: December 18, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Pegvisomant (FDA label)

• Insulin and/or Oral hypoglycemic Agents: Patients with acromegaly and with diabetes mellitus may require careful monitoring and dose reductions of insulin and/or oral hypoglycemic agents. ( 5.2 , 7.1 ) • Opioids: Patients on opioids may need higher SOMAVERT doses to achieve appropriate IGF-1 suppression. ( 7.2 ) 7.1 Insulin and/or Oral Hypoglycemic Agents After initiation of SOMAVERT, patients with acromegaly and diabetes mellitus treated with insulin and/or oral hypoglycemic agents may require dose reductions of insulin and/or oral hypoglycemic agents [see Warnings and Precautions (5.1) ] . 7.2 Opioids In clinical studies, patients taking opioids often needed higher SOMAVERT doses to normalize IGF-1 concentrations compared with patients not receiving opioids. The mechanism of this interaction is not known.

Source: FDA prescribing information (DailyMed). Set ID: 3cbb485b-6df1-49ce-8747-592b395b1988. SPL document ID: 36dc9264-0f75-4059-ac68-65fa4bfcdcc2. Label effective date: December 18, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.